Financial Performance - Jabil reported net revenue of $8.3 billion for the second quarter of fiscal year 2026, with a core operating margin of 5.7%[7][3] - U.S. GAAP diluted earnings per share for the second quarter was $2.08, while core diluted earnings per share (Non-GAAP) was $2.69[7][6] - Net revenue for the three months ended February 28, 2026, was $8,282 million, a 23% increase from $6,728 million in the same period last year[20] - Operating income for the three months ended February 28, 2026, was $374 million, representing a 52% increase compared to $245 million in the same period last year[20] - Net income attributable to Jabil Inc. for the six months ended February 28, 2026, was $369 million, a 70% increase from $217 million in the same period last year[20] - Diluted earnings per share for the three months ended February 28, 2026, was $2.08, up 96% from $1.06 in the same period last year[23] Revenue Outlook - The company raised its fiscal 2026 outlook, projecting net revenue between $34 billion and $34.8 billion, and core diluted earnings per share between $2.83 and $3.23[5][6] Cash Flow and Assets - Jabil's adjusted free cash flow (Non-GAAP) exceeded $1.3 billion, indicating strong cash generation capabilities[8] - Adjusted free cash flow for the six months ended February 28, 2026, was $632 million, compared to $487 million in the prior year, reflecting a 30% increase[25] - Cash flows provided by operating activities for the six months ended February 28, 2026, totaled $734 million, an increase from $646 million in the same period last year[22] - Total cash and cash equivalents at the end of the period was $1,830 million, compared to $1,592 million at the end of the same period last year[22] Operational Highlights - The company experienced robust demand in Intelligent Infrastructure, particularly in cloud and data center infrastructure, networking, and communications[3] - Jabil's total assets increased to $20.628 billion as of February 28, 2026, up from $18.543 billion at the end of August 2025[18] - Current liabilities rose to $14.811 billion, compared to $13.714 billion in the previous period, reflecting increased operational activities[18] Profitability and Growth - Jabil's retained earnings increased to $6.733 billion, up from $6.382 billion, demonstrating improved profitability[18] - The company is focused on profitable growth, disciplined execution, and margin expansion to deliver long-term value for shareholders[3] - Gross profit for the six months ended February 28, 2026, reached $1,488 million, up 26% from $1,182 million in the prior year[20] Adjustments and Acquisitions - The company incurred $848 million in cash paid for business and intangible asset acquisitions during the six months ended February 28, 2026[22] - The company recorded $62 million in adjustments to operating income for the three months ended February 28, 2026, primarily related to restructuring and acquisition charges[23]

Financial Performance - Fourth quarter 2025 revenue was $15.8 million, down 27% year-over-year, but up 44% excluding the maritime business; sequentially, revenue increased 25%[6] - Net loss for the fourth quarter 2025 was $25.1 million, reflecting a 49% year-over-year improvement, and adjusted EBITDA was ($9.7) million, an 8% year-over-year improvement[7] - For the full year 2025, total revenue was $71.6 million, meeting the mid-point of Spire's financial outlook[7] - Revenue for Q4 2025 was $15,825,000, a decrease of 27.1% compared to $21,659,000 in Q4 2024[29] - Net loss for Q4 2025 was $25,094,000, compared to a net loss of $48,783,000 in Q4 2024, showing an improvement[30] - The company reported a net cash used in operating activities of $59,829,000 for the year 2025, compared to $18,453,000 in 2024[32] - The company achieved a gain on the sale of a business amounting to $154,305,000 during the year 2025[29] - For FY 2026, the company projects revenue between $75,000,000 and $85,000,000, with revenue excluding maritime expected to be between $71,300,000 and $81,300,000[37] Cash Flow and Assets - Cash flows used in operations for the fourth quarter 2025 were $4.3 million, representing a 78% year-over-year improvement[8] - Spire's cash, cash equivalents, and marketable securities as of December 31, 2025, were $81.8 million, maintaining a debt-free balance sheet[8] - Cash and cash equivalents rose to $24,813,000 in 2025, compared to $19,206,000 in 2024[31] - Total assets increased to $210,992,000 as of December 31, 2025, up from $193,575,000 in 2024[31] Expenses and Margins - Operating expenses totaled $125,144,000 for the year 2025, an increase of 14.7% from $109,150,000 in 2024[29] - Gross profit for the year ended December 31, 2025, was $29,163,000, down from $39,875,000 in 2024, reflecting a gross margin decline[29] - The fourth quarter 2025 GAAP gross margin improved 8 percentage points year-over-year to 41%[7] - Gross profit (GAAP) for Q4 2025 was $6,432,000, down from $7,010,000 in Q4 2024, representing a decrease of 8.2%[33] - Non-GAAP gross profit for Q4 2025 was $6,867,000, compared to $8,264,000 in Q4 2024, a decline of 17.0%[33] - Research and development expenses were $36,672,000 for the year 2025, an increase of 25.5% from $29,237,000 in 2024[29] - Research and development expenses (GAAP) for Q4 2025 were $8,702,000, down from $10,052,000 in Q4 2024, a decrease of 13.4%[33] - Sales and marketing expenses (GAAP) for Q4 2025 were $2,575,000, down from $6,755,000 in Q4 2024, a significant decrease of 61.9%[33] Future Projections - Spire expects 2026 revenue, excluding maritime revenue, to grow over 50% from 2025, with guidance for Q1 2026 revenue ranging from $14.5 million to $15.5 million[10] - Revenue excluding maritime business for Q1 2026 is expected to change year-over-year by 4% to 12%, and for FY 2026 by 41% to 61%[10] - The projected loss from operations for FY 2026 is between $55,900,000 and $50,700,000, with a non-GAAP loss from operations expected to be between $37,800,000 and $32,600,000[37] - The company anticipates a net loss per share (GAAP) for FY 2026 between $1.65 and $1.49, with a non-GAAP net loss per share projected between $1.11 and $0.96[37] - For Q1 2026, revenue is expected to range from $14,500,000 to $15,500,000, with revenue excluding maritime projected between $12,800,000 and $13,800,000[36] Contracts and Developments - In Q4 2025, Spire launched 12 satellites and shipped 9 satellites for a launch completed in January 2026, enhancing its capabilities in space reconnaissance and weather forecasting[11] - Spire was awarded a contract with a shared ceiling of $151 billion for the Missile Defense Agency's SHIELD program, allowing for rapid delivery of innovative capabilities[11]

Revenue Growth - Annual Recurring Revenue (ARR) grew 28% year-over-year to $1.125 billion, with SaaS ARR increasing 38% year-over-year to $746 million[7]. - Total revenue for fiscal year 2026 was $1.071 billion, reflecting a 24% year-over-year increase, while subscription revenue rose 27% year-over-year to $1.010 billion[8]. - For Q1 FY 2027, SailPoint expects total ARR guidance of $1,153 to $1,157 million, representing a year-over-year growth of 25%[9]. - Total revenue guidance for FY 2027 is projected to be between $1,260 to $1,270 million, with a year-over-year growth of 18% to 19%[9]. - Total revenue for the three months ended January 31, 2026, was $294,647,000, representing a 23% increase from $240,121,000 in the same period of 2025[44]. - Subscription revenue for the three months ended January 31, 2026, reached $280,778,000, a 25% increase compared to $224,379,000 in the prior year[44]. - The company’s total subscription revenue for the year ended January 31, 2026, was $1,010,198,000, a 27% increase from $793,919,000 in 2025[44]. Profitability and Loss - Operating loss for fiscal Q4 2026 was $(40) million, or (14)% of revenue, compared to $(30) million, or (13)% of revenue in fiscal Q4 2025[8]. - Adjusted income from operations for fiscal Q4 2026 was $61 million, or 21% of revenue, up from $46 million, or 19% of revenue in fiscal Q4 2025[8]. - The net loss for the year ended January 31, 2026, was $270,054,000, a decrease from a net loss of $315,830,000 in 2025[37]. - The company reported a net loss of $36,215,000 for the three months ended January 31, 2026, an improvement from a net loss of $80,104,000 in the same period of 2025[42]. - GAAP net loss for the three months ended January 31, 2026, was $36,215,000, compared to a loss of $270,054,000 for the year[50]. - Adjusted net income for the year ended January 31, 2026, was $132,685,000, with an adjusted EPS of $0.24[50]. Cash Flow and Financial Position - Cash flows from operating activities in fiscal Q4 2026 were $64 million, with free cash flow of $57 million[7]. - Cash, cash equivalents, and restricted cash at the end of the period totaled $361,386,000, significantly up from $124,390,000 at the end of the previous year[42]. - Cash and cash equivalents as of January 31, 2026, were $358,144,000, significantly higher than $121,293,000 as of January 31, 2025[40]. - Net cash provided by operating activities for the three months ended January 31, 2026, was $63,864,000, compared to $13,794,000 in the same period of 2025[42]. - The company’s cash flows from investing activities for the three months ended January 31, 2026, were a net outflow of $6,894,000, compared to a net outflow of $12,663,000 in the same period of 2025[42]. Expenses - Research and development expenses increased to $56,366,000 for the three months ended January 31, 2026, up from $45,456,000 in the prior year[37]. - GAAP research and development expense for the three months ended January 31, 2026, was $56,366,000, up from $45,456,000 in 2025[47]. - GAAP sales and marketing expense for the three months ended January 31, 2026, was $140,692,000, an increase from $116,865,000 in 2025[48]. - GAAP general and administrative expense for the three months ended January 31, 2026, was $41,325,000, up from $27,665,000 in 2025[48]. - Adjusted research and development expense for the three months ended January 31, 2026, was $46,327,000, compared to $39,505,000 in 2025[47]. - Adjusted sales and marketing expense for the three months ended January 31, 2026, was $104,234,000, compared to $87,368,000 in 2025[48]. Future Outlook - The company aims to secure every type of identity, positioning itself as a foundational identity control plane for AI-powered enterprises[4]. - The company anticipates continued growth in the identity security solutions market, with expectations for future revenue growth and operational improvements[34]. - SailPoint's adjusted operating margin for FY 2027 is projected to be between 18.2% to 18.8%[9].

Revenue Performance - Total revenue for Q4 2025 was $3.1 million, a 62% increase compared to $1.9 million in Q4 2024, and a sequential increase of 25% from Q3 2025[5] - U.S. revenue for Q4 2025 was $0.9 million, reflecting a sequential growth of 74% during the second quarter of CGuard Prime's launch, while international revenue was $2.3 million, a 17% increase over Q4 2024[6] - For the full year 2025, total revenue was $9.0 million, a 28% increase from $7.0 million in 2024, with U.S. revenue at $1.4 million and international revenue at $7.6 million, an 8% increase over 2024[13] - The company expects full year 2026 revenue to be in the range of $13 million to $15 million, reflecting a growth of approximately 45% to 65% over 2025[19] Profit and Loss - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $0.5 million, or 24.1% of revenue, in Q4 2024, driven by a favorable sales mix[7] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million, or $0.19 per share, in Q4 2024[12] Operating Expenses - Total operating expenses for Q4 2025 were $13.3 million, an increase of $3.5 million compared to $9.8 million in Q4 2024, primarily due to increased headcount-related expenses[10] Cash and Securities - As of December 31, 2025, cash and cash equivalents and marketable securities totaled $54.2 million, up from $34.6 million as of December 31, 2024[17] Liabilities and Equity - Total liabilities increased to $14,203 million in 2025 from $10,721 million in 2024, representing a growth of 32.7%[31] - Total equity rose to $55,201 million in 2025, up from $36,086 million in 2024, marking a significant increase of 53.0%[31] - Current liabilities reached $10,712 million in 2025, compared to $7,678 million in 2024, reflecting a 39.4% increase[31] - Long-term liabilities grew to $3,491 million in 2025, up from $3,043 million in 2024, indicating a rise of 14.7%[31] - Additional paid-in capital increased to $357,489 million in 2025 from $289,589 million in 2024, a growth of 23.5%[31] - The accumulated deficit widened to $(302,292) million in 2025 from $(253,506) million in 2024, an increase of 19.2%[31] - The number of common shares issued and outstanding increased to 43,532,281 in 2025 from 26,611,033 in 2024, a rise of 63.5%[31] - The total assets, as indicated by total liabilities and equity, reached $69,404 million in 2025, up from $46,807 million in 2024, representing a growth of 48.2%[31] - Operating lease liabilities net of current maturities increased to $2,224 million in 2025 from $1,796 million in 2024, a rise of 23.8%[31] - The liability for employee rights upon retirement and others slightly increased to $1,267 million in 2025 from $1,247 million in 2024, a growth of 1.6%[31] Clinical and Regulatory Updates - The company supported over 500 cumulative carotid procedures utilizing CGuard Prime since its launch[8] - The company completed enrollment in the CGUARDIANS II pivotal trial for CGuard Prime designed for TCAR procedures and submitted a PMA-S to the FDA for approval[8]

Product Development and Approval - The company has developed two commercial products: Elelyso for Gaucher disease and Elfabrio for Fabry disease, both of which are enzyme replacement therapies (ERTs) approved in over 40 and 20 markets respectively[17][20]. - Elelyso was first approved by the FDA in 2012 and is marketed in more than 40 markets, while Elfabrio received FDA approval in May 2023 and is now available in over 10 additional markets[18][21]. - The company is actively recruiting for a Phase 2 clinical trial of PRX-115 for uncontrolled gout, known as the RELEASE study, following the completion of a Phase 1 trial[16][26]. - The Phase 3 clinical program for Elfabrio included three studies, analyzing two dosing regimens: 1 mg/kg E2W and 2 mg/kg E4W[57]. - In the Phase 1 clinical trial of PRX-115 for uncontrolled gout, 64 subjects were enrolled, with 48 receiving the treatment and 16 receiving placebo[68]. - The pediatric study for Elfabrio is ongoing, assessing safety and efficacy in patients aged 2 to less than 18 years[61]. - The RELEASE study for PRX-115 aims to enroll approximately 150 adult patients across clinical sites in the US, Georgia, and Israel[64]. Clinical Trial Results - PRX-115 demonstrated a dose-dependent increase in exposure, with detectable levels in plasma for up to 12 weeks in higher dose cohorts[69]. - A single dose of PRX-115 rapidly reduced plasma urate levels, maintaining levels below 6.0 mg/dL for up to 12 weeks at the highest doses[72]. - 25% of subjects treated with PRX-115 reported drug-related adverse events, primarily mild to moderate[78]. - Approximately 50% of subjects developed anti-drug antibodies (ADAs), with higher incidence in lower dose cohorts[78]. - The safety and immunogenicity profile of PRX-102 is consistent with other enzyme replacement therapies[60]. - The company has observed serious adverse events during clinical trials of Elfabrio, including treatable anaphylactic reactions, which could impact future product development and approval[209]. Market and Financial Overview - The global market for Gaucher disease therapies is projected to be approximately $1.6 billion in 2026, with a CAGR of 0.5% from 2025 to 2031[45]. - The global market for Fabry disease therapies is forecasted to reach approximately $2.3 billion in 2026, growing at a CAGR of 6.3% from 2025 to 2031, potentially reaching $3.2 billion by 2031[53]. - The company heavily relies on revenues from Elfabrio and Elelyso, with any failure in commercialization having a material adverse effect on business and financial condition[208]. - Significant investment has been made in the development of Elfabrio, with future revenue generation dependent on Chiesi's successful commercialization efforts, which are not under the company's control[208]. - Sales of Elelyso are also dependent on Pfizer's efforts, with the company having no control over these sales except in Brazil, where sales are managed by Fiocruz[208]. Partnerships and Collaborations - The company has partnered with Chiesi for the global commercialization of Elfabrio, which includes upfront payments and potential milestone payments[23]. - Chiesi has made an upfront payment of $25 million for the exclusive license to commercialize Elfabrio outside the US, with potential additional payments up to $270 million[90]. - Protalix Ltd. has licensed global rights to market Elelyso to Pfizer, with fixed-cost sales through 2030[84]. - Protalix Ltd. received a milestone payment of $20 million following FDA approval of Elfabrio, with potential additional payments up to $740 million[92]. Technology and Manufacturing - The ProCellEx platform is utilized for the production of both approved products and ongoing clinical candidates, allowing for the development of complex recombinant proteins[30][31]. - The company’s proprietary ProCellEx technology offers advantages such as biologic optimization and elimination of viral contamination risks, enhancing the production of therapeutic proteins[32][36]. - The manufacturing facility in Carmiel, Israel, spans approximately 1,466 sq/m and is compliant with cGMP standards for drug production[108]. - The facility's current capacity meets all commercial and clinical needs, with plans for expansion to enhance purification capabilities for future product commercialization[109]. - The FDA and other regulatory authorities have conducted successful inspections of the manufacturing facilities, ensuring compliance with safety and quality standards[110]. Regulatory Environment - All clinical trials must be conducted under GCP regulations, requiring informed consent from participants and IRB approval before commencement[117]. - The FDA may take one to three years to approve a BLA or NDA, and additional clinical data may be required if regulatory criteria are not met[125]. - Orphan Drug Designation can be granted for drugs treating rare diseases, providing benefits such as funding and tax savings, but does not expedite the regulatory review process[128]. - The FDA's Fast Track and Breakthrough Therapy designations facilitate expedited development and review for drugs addressing serious conditions[132]. - Accelerated Approval allows drugs to be marketed based on surrogate endpoints, contingent on post-approval studies to confirm clinical benefits[137]. - Post-approval requirements include ongoing compliance with FDA regulations, record-keeping, and reporting of adverse effects[138]. - Manufacturers must register with the FDA and are subject to inspections to ensure compliance with cGMP standards throughout the manufacturing process[139]. - The FDA may withdraw product approval if regulatory compliance is not maintained or if new safety issues arise post-approval[140]. Tax and Financial Incentives - Protalix Ltd. benefits from the Israeli government's tax incentives under the Investment Law, with a corporate tax rate of 23% applicable from 2018 onwards[157]. - The company has been granted "Approved Enterprise" status, allowing for a 10-year tax exemption on undistributed income from its facility located in a Zone A area[165]. - The Investment Law provides accelerated depreciation benefits on property and equipment included in approved investment programs, regardless of the benefits program elected[169]. - Protalix Ltd. must comply with specific conditions to maintain its tax benefits, with potential penalties for non-compliance, including refunding benefits received[170]. Competition and Market Challenges - The company faces significant competition in the biotechnology and pharmaceutical industries, with established companies having substantial resources[103]. - In the treatment of Gaucher disease, competition includes Sanofi Genzyme's Cerezyme and Takeda's Vpriv, among others[104]. - For Fabry disease, the primary competitors are Sanofi Genzyme's Fabrazyme and Takeda's Replagal, with other experimental drugs in development[105]. - The company is aware of potential competition to its ProCellEx system from various companies developing alternative expression technologies[107]. - The company faces uncertainty regarding third-party payor coverage and reimbursement, which is critical for the commercialization of its products[147]. - Legislative changes in the U.S. focused on cost containment and price transparency may impact the company's profitability and regulatory burdens[150]. - The company must navigate complex pricing and reimbursement schemes in various countries, which can create high barriers to market entry for new products[152]. Workforce and Employment - As of December 31, 2025, Protalix Ltd. employed 226 full-time employees, an increase from 213 in 2024 and 208 in 2023[185]. - The company has a research and development team of 62 employees as of December 31, 2025, up from 48 in 2024[185]. Risks and Uncertainties - The company has a risk of needing to raise additional capital to operate its business, which may not be available on favorable terms[203]. - Protalix Ltd. may face challenges in obtaining necessary regulatory approvals for its drug candidates, impacting commercialization timelines[197]. - The company’s operations may be adversely affected by military, political, and economic conditions in Israel[205].

Sales Performance - Macy's, Inc. reported fourth quarter net sales of $7.6 billion, a decrease of 1.7% compared to the fourth quarter of 2024, with comparable sales up 1.8%[3] - Bloomingdale's achieved a remarkable 9.9% increase in comparable sales during the fourth quarter[4] - For fiscal year 2025, Macy's, Inc. net sales decreased 2.4% to $21.8 billion, while comparable sales grew 1.5%[8] - Net sales for the 13 weeks ended January 31, 2026, were $7,639 million, a decrease from $7,768 million for the same period in 2025[30] - Total revenue for the 52 weeks ended January 31, 2026, was $22,621 million, compared to $23,006 million for the previous year, reflecting a decline of 1.7%[33] - For the 13 weeks ended January 31, 2026, net sales were $7,639 million, a decrease of 1.7% compared to $7,768 million for the same period in 2025[41] Financial Performance - The company generated operating cash flow of $1.4 billion and free cash flow of $0.8 billion, ending the year with $1.2 billion in cash and cash equivalents[4] - Macy's, Inc. achieved GAAP diluted EPS of $1.84 and adjusted diluted EPS of $1.67, both exceeding guidance[4] - Operating income for the 13 weeks ended January 31, 2026, increased to $745 million, representing 9.4% of total revenue, up from $500 million or 6.2% in the prior year[30] - Net income for the 52 weeks ended January 31, 2026, was $642 million, compared to $582 million for the previous year, marking a year-over-year increase of 10.3%[33] - Basic earnings per share for the 13 weeks ended January 31, 2026, rose to $1.91, up from $1.23 in the same period last year[30] - Adjusted EBITDA for the 13 weeks ended January 31, 2026, was $840 million, compared to $903 million for the same period in 2025, reflecting a decrease of 7%[49] - The company reported net income of $507 million for the 13 weeks ended January 31, 2026, compared to $342 million for the same period in 2025, an increase of 48.3%[49] - Free cash flow for the 52 weeks ended January 31, 2026, was $797 million, an increase from $679 million for the 52 weeks ended February 1, 2025[51] Revenue Sources - Other revenue increased by 20.2% to $857 million, driven by strong performance in credit card revenues and Macy's Media Network[8] - Other revenue sources, including Macy's Media Network, contributed $72 million for the 13 weeks ended January 31, 2026, up from $64 million in the prior year[41] - Credit card revenues for the 13 weeks ended January 31, 2026, increased to $205 million, representing 2.7% of net sales, up from $175 million or 2.3% in the prior year[41] Cost and Expenses - SG&A expenses for fiscal year 2025 decreased by $90 million to $8.2 billion, but as a percentage of total revenue, it increased to 36.4%[9] - Gross margin for the 52 weeks ended January 31, 2026, was $8,267 million, representing 38.0% of net sales, compared to $8,553 million or 38.4% in the previous year[33] - Gross margin for the 52 weeks ended January 31, 2026, was impacted by various costs, with total EBITDA reported at $1,873 million, up from $1,760 million in the previous year[49] Future Outlook - The company plans to expand its strategic initiatives to 75 additional stores under the "Reimagine 200" program for 2026[1] - For fiscal year 2026, Macy's, Inc. expects net sales between $21.4 billion and $21.65 billion, with comparable sales change projected between -0.5% and 0.5%[20] Assets and Liabilities - Total assets as of January 31, 2026, were $16,238 million, a slight decrease from $16,402 million as of February 1, 2025[35] - Current liabilities decreased to $4,493 million as of January 31, 2026, compared to $4,524 million in the previous year[35] - Long-term debt decreased to $2,432 million as of January 31, 2026, down from $2,773 million as of February 1, 2025[35] Taxation - The effective income tax rate for the 13 weeks ended January 31, 2026, was 23.4%, compared to 21.6% for the same period in 2025, primarily due to state and local taxes[41] Losses - The company experienced a net loss from interchange fee settlements of $328 million for the 13 weeks ended January 31, 2026, compared to no such losses in the previous year[49]

Financial Performance - Net sales for the third quarter were $4.4 billion, down 8 percent, with a 6-point headwind from divestitures and acquisitions; organic net sales decreased by 3 percent[5]. - Operating profit for the third quarter was $525 million, down 41 percent, with an operating profit margin of 11.8 percent, a decrease of 660 basis points[6]. - Diluted earnings per share (EPS) for the third quarter were $0.56, down 50 percent; adjusted diluted EPS was $0.64, down 37 percent in constant currency[7]. - Gross margin decreased by 310 basis points to 30.8 percent of net sales, primarily due to higher input costs, partially offset by favorable net price realization[6]. - The company reported net earnings attributable to General Mills of $303.1 million for the quarter ended February 22, 2026, down 52% from $625.6 million in the same quarter last year[37]. - Operating profit for the total segments decreased by 26% to $628.8 million, with North America Retail segment operating profit down 33% to $436.1 million[40]. - Adjusted operating profit for the nine-month period ended February 22, 2026, was $2,106.1 million, down 23% from $2,730.1 million in the prior year[74]. - Adjusted net earnings attributable to General Mills for the quarter were $342.5 million, or 7.7% of net sales, compared to $551.3 million, or 11.4% of net sales in the prior year[79]. Segment Performance - The North America Retail segment reported a 14 percent decline in net sales to $2.6 billion, impacted by a 9-point headwind from yogurt divestitures[15]. - The North America Pet segment saw a 3 percent increase in net sales to $640 million, benefiting from a 6-point contribution from the Whitebridge Pet Brands acquisition[17]. - The International segment's net sales increased by 7 percent to $696 million, with a 6-point benefit from foreign currency exchange; organic net sales were up 1 percent[22]. - North America Retail segment net sales fell by 14% to $2,596.4 million, while International segment net sales increased by 7% to $696.3 million[40]. - North America Retail segment operating profit decreased by 33% for the quarter, while the International segment saw an increase of 87%[84]. Future Outlook - The company reaffirmed its full-year fiscal 2026 outlook, expecting improved organic sales trends and earnings growth in the fourth quarter[3]. - For fiscal 2026, organic net sales are expected to decline by 1.5 to 2 percent, with adjusted operating profit and adjusted diluted EPS projected to decrease by 16 to 20 percent in constant currency[34]. - The Company anticipates a reduction in adjusted operating profit growth by approximately 5 points due to the net impact of divestitures and acquisitions in fiscal 2026[30]. - The company expects net sales growth to be reduced by approximately 4% due to foreign currency exchange rates and completed acquisitions and divestitures[60]. Cash Flow and Investments - Cash provided by operating activities totaled $1.6 billion through nine months of fiscal 2026, down from $2.3 billion a year ago[28]. - The company reported a net cash provided by operating activities of $1,614.2 million for the nine-month period ended February 22, 2026, down from $2,306.6 million in the prior year[46]. - Cash and cash equivalents increased to $785.5 million as of February 22, 2026, compared to $521.3 million a year earlier[43]. - The Company plans to invest significantly in consumer value and innovation, including launching Blue Buffalo into the U.S. fresh pet food sub-category[29]. - Free cash flow conversion is expected to be at least 95% of adjusted after-tax earnings[34]. Restructuring and Charges - Restructuring and transformation costs totaled $24 million in the third quarter, compared to a net recovery of $1 million in the prior year[26]. - Restructuring charges in the third quarter of fiscal 2026 totaled $25 million, with an expected total of approximately $96 million for the multi-year supply chain initiative, including $28 million in cash[49]. - Restructuring and transformation charges for fiscal 2026 are projected to total approximately $175 million to $180 million[60]. - The company anticipates completing restructuring actions related to supply chain initiatives by the end of fiscal 2029[49]. Tax and Shares - The effective tax rate for the third quarter was 24.3 percent, compared to 19.8 percent in the previous year[27]. - The effective tax rate for the third quarter of fiscal 2026 was 24.3%, an increase from 19.8% in the same period last year[55]. - The average number of diluted shares for the quarter is 537.3 million[88]. - Average diluted shares outstanding decreased by 4% to 539 million through nine months of fiscal 2026[28]. Acquisitions and Divestitures - The company completed the acquisition of NX Pet Holding, Inc. for $1 billion, consolidating it into the North America Pet segment[48]. - The company entered into a definitive agreement to sell its business in Brazil for a base purchase price of R$800 million, expecting a pre-tax loss including $622 million in accumulated foreign currency translation losses[49]. - The company recorded a pre-tax gain of $1,046 million from the sale of its United States yogurt business in fiscal 2026[52]. - The company reported a divestiture loss of $1,049.4 million for the nine-month period, impacting net earnings significantly[81]. - The company reported a divestitures loss of $95.9 million for the nine-month period ended February 23, 2025[88].

Revenue Performance - Revenues from selling goods for the fiscal year 2025 were $51.8 million, a decrease of 2% compared to $53.0 million in 2024, primarily due to a $6.8 million decline in sales to Chiesi[12]. - Total revenue for 2023 was $65.494 million, with a projected decrease to $53.399 million in 2024 and further to $52.744 million in 2025[27]. - Full-year 2026 revenues from sales of Elfabrio are expected to range from approximately $33.0 million to $35.0 million[10]. Financial Position - The company has a strong cash position with cash, cash equivalents, and short-term bank deposits totaling $30.3 million as of December 31, 2025[19]. - Cash and cash equivalents decreased from $19.760 million in 2024 to $14.680 million in 2025[26]. - Total current assets increased from $60.078 million in 2024 to $66.673 million in 2025[26]. - The company has no outstanding debt or warrants, positioning it for durable growth and long-term value[8]. Expenses and Losses - Research and development expenses increased by 51% to $19.6 million in 2025, driven by preparations for the RELEASE Phase 2 study of PRX-115[12]. - Research and development expenses are projected to rise from $12.970 million in 2024 to $19.569 million in 2025[27]. - The company reported a net loss of approximately $6.6 million for the year ended December 31, 2025, compared to a net income of $2.9 million in 2024[19]. - Operating income is expected to decline from $3.917 million in 2024 to a loss of $5.500 million in 2025[27]. - Net income for 2023 was $8.312 million, expected to decline to $2.932 million in 2024 and result in a loss of $6.604 million in 2025[27]. Clinical Development - The Phase 2 clinical trial of PRX-115 is actively enrolling, with top-line results anticipated in the second half of 2027[9]. - Management expects total revenues in 2026 to range from approximately $78.0 million to $83.0 million, including the $25.0 million milestone payment[10]. Strategic Focus - The company is focusing on rare renal diseases with PRX-119 and advancing its RNA-based discovery collaboration with Secarna[2]. - The European Commission approved the 2mg/kg every-4-weeks dosing regimen for Elfabrio, which triggered a $25.0 million milestone payment from Chiesi, strengthening the company's cash position[3]. Risks and Challenges - The company anticipates risks related to the commercialization of its product Elfabrio® and potential regulatory challenges[21]. - Total liabilities are expected to rise from $30.206 million in 2024 to $34.116 million in 2025[26]. - Accounts receivable increased significantly from $2.909 million in 2024 to $8.840 million in 2025[26].

Corporate Updates - XOMA Royalty Corporation updated its corporate presentation on March 2, 2026, which includes key financial results and operational insights[5]. - The updated presentation is referenced in Item 2.02, indicating significant financial data is available on pages 10-11 of the document[4]. Stock Information - The company is listed on the Nasdaq Global Market under the ticker symbol XOMA, with a par value of $0.0075 per share for common stock[2]. Financial Reporting - The company has not elected to use the extended transition period for complying with new financial accounting standards, indicating a commitment to timely reporting[3]. - The report does not include specific financial metrics or performance indicators, suggesting further details may be found in the attached corporate presentation[6].

Merger and Acquisition - The Company completed a merger with Vyome Therapeutics, Inc. on August 15, 2025, resulting in the renaming to Vyome Holdings, Inc. [534] - A 1-for-4 reverse stock split was executed on August 15, 2025, to comply with Nasdaq listing requirements [551] - Transactional fees related to the Merger amounted to approximately $7,705,533 in 2025, with $5.9 million in shares issued to advisors and $1.8 million in cash payments [585] - General and administrative expenses increased significantly to $2,365,565 in 2025, a rise of $1,466,993 (163.5%) from $898,572 in 2024, driven by legal and professional fees related to the Merger [582] Financial Performance - Revenue for the year ended December 31, 2025, was $319,714, an increase of $62,770 (24.4%) compared to $256,944 in 2024 [578] - The net loss for the year ended December 31, 2025, was $10,477,713, compared to a net loss of $1,447,461 in 2024, reflecting an increase of $9,030,252 (623.5%) [578] - Cash used in operating activities for 2025 was $3,748,853, a significant increase of $3,134,717 compared to $614,136 in 2024 [588] - The Company reported a net increase in cash and cash equivalents of $4,880,429 for the year ended December 31, 2025, compared to an increase of $85,257 in 2024 [587] Research and Development - The lead program, VT-1953, is a topical gel for treating malignant fungating wounds, with discussions planned with the FDA for a pivotal trial in Q2 2026 [535] - Research and development expenses rose to $588,258 in 2025, up $302,867 (106.1%) from $285,391 in 2024, primarily due to resumed R&D activities post-Merger [581] - The Company has a development and licensing agreement for MRT technology-based Luliconazole topical cream, generating revenues from milestone payments and royalties [563] Funding and Capital Requirements - A private placement raised $5.75 million through the sale of 520,514 shares at $11.02 per share [550] - The company raised net proceeds of approximately $5,291,868 from the sale of common stock from January 1, 2026, through March 12, 2026 [596] - Future capital requirements will depend on various factors, including the costs of clinical trials, manufacturing, and commercialization activities [599] - The company believes existing cash and proceeds from financing will fund operating expenses for at least 15 months, but not sufficient to complete pivotal trials or develop other product candidates [596] - The company may need substantial additional funding to support operations and growth strategy, potentially through equity offerings, debt financings, or collaboration agreements [595] Operational Aspects - The Company operates in two segments: biotechnology (VT-1953, VT-1908, VB-1953) and pharmaceutical products (anti-fungal products) [538] - The Company has not generated revenue from its biotechnology segment, while the pharmaceutical segment is based on legacy licensing agreements [539] - The company has entered into agreements for sponsored research and clinical trials, which are generally cancellable upon written notice [601] - The company leases office and laboratory space in India with monthly payments ranging from $2,500 to $2,900, extended until December 2026 [602] Economic Conditions - Inflation has not had a material effect on the company's business or financial condition during the years ended December 31, 2025, or 2024 [610] - The Company expects general and administrative expenses to continue increasing as it expands to support growth in research and development activities [572] - The company expects to incur significant and increasing expenses and operating losses for the foreseeable future as it advances product candidates through development and regulatory approval [592]